POSB51 A Cost-Effectivess Analysis of Trastuzumab Emtansine Versus Trastuzumab for the Adjuvant Treatment of Patients with Residual Invasive HER2-Positive Breast Cancer in Portugal
Abstract
Authors
L Silva Miguel B Pinheiro R Lopes C Revil I Monteiro M Borges